Research · PMID 15184489
Review date on record: Sep 2026. Named clinician approval is not independently verified on this page.
Subtype B human immunodeficiency virus (HIV) type 1 mutant that escapes detection in a fourth-generation immunoassay for HIV infection.
Journal of clinical microbiology · June 2004 · Catherine Gaudy, Alain Moreau, Sylvie Brunet, Jean-Michel Descamps, Pascale Deleplanque, et al.
What this study found
We report a case of human immunodeficiency virus (HIV) type 1 infection not detected by a highly sensitive combined antigen-antibody assay. The virus was a subtype B strain harboring a unique sequence within the immunodominant epitope of the transmembrane glycoprotein.
How RAGMD uses this study
Clinical questions this paper informs
Synthesis lives on the evidence question — this page shows where the study sits in that analysis.
Supporting literature
How effective are PDE5 inhibitors for erectile dysfunction?
PDE5 inhibitors substantially improve erectile function versus placebo across broad ED populations, with landmark trials showing clinically meaningful IIEF improvements. On-demand dosing before sexual activity is standard; response rates are high though not universal.
Open evidence analysisSupporting literature
Is daily low-dose tadalafil better than on-demand dosing for erectile dysfunction?
Both daily low-dose and on-demand tadalafil improve erectile function. Daily dosing may improve spontaneity and lower urinary symptom scores in men with comorbid LUTS, while on-demand dosing minimizes drug exposure for men with infrequent sexual activity.
Open evidence analysisSupporting literature
Are PDE5 inhibitors safe for cardiovascular disease in men with erectile dysfunction?
In stable cardiovascular disease, PDE5 inhibitors do not appear to increase major adverse cardiac events when used appropriately and nitrate co-administration is avoided. Sexual activity itself carries modest cardiovascular demand; individualized assessment remains important after recent events.
Open evidence analysisSupporting literature
Why are PDE5 inhibitors contraindicated with nitrates?
Combined PDE5 inhibition and nitric oxide donor therapy can produce profound synergistic vasodilation and symptomatic hypotension. Nitrates and PDE5 inhibitors should not be used together; allow appropriate washout intervals when switching between agents in acute coronary care.
Open evidence analysisSupporting literature
Is erectile dysfunction a marker of future cardiovascular disease?
Erectile dysfunction often precedes symptomatic cardiovascular disease and shares endothelial dysfunction pathways with atherosclerosis. Men presenting with ED warrant cardiovascular risk assessment and conventional prevention strategies independent of PDE5 therapy decisions.
Open evidence analysisSupporting literature
Does testosterone therapy improve erectile function in hypogonadal men?
Testosterone improves sexual desire and some erectile function endpoints in men with confirmed hypogonadism, but effects are smaller than PDE5 inhibitors for vascular erectile dysfunction. Treat documented deficiency when indicated; do not rely on testosterone alone for moderate-to-severe ED without evaluating PDE5 therapy.
Open evidence analysisSupporting literature
What options exist for men who do not respond to PDE5 inhibitors?
Optimize dosing timing, adherence, and comorbidity management before labeling true non-response. Switching PDE5 agents, adding lifestyle and vascular risk-factor control, vacuum devices, intracavernosal therapy, or referral for specialized evaluation are evidence-supported pathways when oral therapy fails.
Open evidence analysisSupporting literature
What treatments are effective for premature ejaculation?
On-demand dapoxetine and daily or on-demand SSRIs lengthen intravaginal ejaculatory latency and improve control in men with lifelong or acquired premature ejaculation. Behavioral therapy and topical anesthetics are adjunctive options depending on preference and side-effect tolerance.
Open evidence analysis